VA Launches MDMA-Assisted Therapy Trial for Veterans With PTSD

The Department of Veterans Affairs announced on May 26, 2026 a new randomized controlled trial to test whether MDMA-assisted therapy can treat military veterans diagnosed with both post-traumatic stress disorder and alcohol use disorder — a combination that VA data show affects roughly 63% of veterans presenting for substance use treatment.

The trial, titled “A Randomized Controlled Trial of MDMA-Assisted Therapy for PTSD and Alcohol Use Disorder in U.S. Veterans” and registered with ClinicalTrials.gov (NCT07118839), began enrolling participants on May 18, 2026. About 80 veterans will be recruited from VA Providence Healthcare System in Rhode Island and VA Connecticut Healthcare System in West Haven, Connecticut. Results are expected by May 2030.

Participants will be randomly assigned to receive either MDMA-assisted psychotherapy or an identical psychotherapy protocol with an active placebo. Sessions will use pharmaceutical-grade MDMA in a controlled clinical setting with two clinicians present throughout — a resource-intensive protocol that VA Secretary Doug Collins told lawmakers requires roughly 120 hours per patient. The VA is coordinating with the FDA and plans to share trial data with the agency; clinical use outside the research setting remains off the table unless and until FDA grants formal approval.

The trial builds directly on prior research at the Providence site. Principal investigator Erica M. Eaton of the Providence VA Medical Center led a prior open-label pilot study, published in 2024 in Contemporary Clinical Trials Communications, that documented the procedural groundwork for conducting MDMA-assisted therapy at VA facilities — securing FDA authorization for investigational use, obtaining DEA Schedule I research licensing, and training six therapists in the protocol. The new randomized design is the next stage in that work.

What the Phase 3 Evidence Shows — and Where It Fell Short

Two pivotal studies, both funded by MAPS Public Benefit Corporation and published in Nature Medicine, form the scientific case for MDMA-assisted therapy in PTSD.

MAPP1, published in 2021, was the first Phase 3 randomized controlled trial of the treatment. It found that 88% of participants in the MDMA arm showed clinically meaningful improvement on the Clinician-Administered PTSD Scale, and 67% no longer met diagnostic criteria for PTSD after three sessions — compared to 32% in the placebo group. MAPP2, a confirmatory Phase 3 study of 104 adults published in Nature Medicine in September 2023, extended those findings to a broader and more diverse population with moderate-to-severe PTSD: 71% of participants receiving MDMA-assisted therapy no longer met PTSD criteria at study end, compared to 48% in placebo.

Those are large effect sizes by psychiatric drug trial standards. But the evidence package ran into serious methodological objections at FDA. In June 2024, the FDA’s Psychopharmacologic Drugs Advisory Committee voted 10-1 that the Lykos Therapeutics application failed to show benefits outweigh risks, and 9-2 that the data did not demonstrate efficacy. The agency’s core concern: MDMA’s acute subjective effects make true blinding nearly impossible. Participants in the MDMA arm could feel they were receiving the active drug, introducing expectancy bias that conventional analysis can’t fully disentangle. The panel also raised concerns about therapist conduct at one trial site. In August 2024, the FDA declined to approve the therapy and called for an additional Phase 3 study.

The VA trial targets a gap the MAPP program couldn’t address. An exploratory finding from MAPP1 showed MDMA-assisted therapy was associated with significantly greater reductions in hazardous alcohol use scores compared to placebo — a signal worth pursuing, but one MAPP2 couldn’t follow up on because participants with moderate-to-severe alcohol use disorder were excluded from that study. The VA trial puts the dual diagnosis at the center of the design rather than treating it as a secondary concern.

Why the Combined Diagnosis Changes the Research Question

PTSD and alcohol use disorder co-occur in a large share of the veteran population. VA data suggest about 63% of veterans entering substance use treatment also carry a PTSD diagnosis — making combined-condition care a clinical priority that standard sequential approaches handle poorly. Dropout rates for first-line PTSD psychotherapies like prolonged exposure have reached 55% or higher in some veteran cohorts; the MAPP trials consistently observed substantially lower dropout in the MDMA arm, an effect researchers attribute to the drug’s tendency to soften threat responses and deepen therapeutic engagement.

Whether those dynamics hold when both PTSD and alcohol use disorder are primary clinical targets — rather than when alcohol use disorder is excluded to simplify the trial — is the open question this study is designed to answer.

The functional unblinding problem remains methodologically unresolved. MDMA’s effects are unmistakable, and an active placebo reduces but can’t eliminate the asymmetry in expectation between trial arms. The FDA’s objections to the MAPP data were not answered by those trials, and a new study using a similar design will face the same scrutiny when its results arrive. What’s different here is the institutional provenance: the VA is running a federally coordinated, government-funded trial whose data will be shared directly with FDA — meaningfully different from research funded and conducted by an advocacy-adjacent nonprofit, even when the underlying methodology carries similar limitations.

The new trial fits within a broader federal push that accelerated after Trump’s executive order in April 2026 directing agencies to expand psychedelic therapy research. Public support for regulated psychedelic therapy has grown sharply in recent years, and a separate effort to open VA doctors to recommending medical cannabis has advanced in Congress. The VA now supports 19 active psychedelic clinical trials backed by more than $23 million in external funding. Results from the Providence and West Haven sites are expected in May 2030 — four years out from a field that hoped to have an approved MDMA therapy on the market well before now.